Azura Ophthalmics

Azura Ophthalmics is a clinical-stage company dedicated to developing an innovative portfolio of compounds to advance the treatment of MGD (the leading cause of DED). By targeting the root cause of MGD, Azura brings hope for improved health outcomes to millions of people worldwide who suffer from MGD and other ocular surface diseases that currently lack therapeutic options. Azura is supported by an experienced management team with a proven track record of successfully developing and commercializing new therapies for ocular surface diseases.